Plain-English translation of NCT07781852 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing two versions of a new imaging agent called CM500 that doctors inject into the body before special PET scans. The goal is to understand whether CM500 is safe, how it moves through the body, and whether it can help detect different types of cancer. Researchers will study both healthy volunteers and people with cancer to learn how this medication works.
Current imaging methods have limitations in detecting and monitoring certain cancers. Researchers hope this new medication will provide doctors with a better tool to find and track cancer cells in the body.
If you are selected, you will receive an injection of the test medication and then undergo one or more PET scans (either PET/CT or PET/MRI). You will also have blood samples taken before, during, and after your scan to help researchers understand how the medication moves through your body and is processed. For healthy volunteers, this helps establish safety; for cancer patients, it helps show whether the medication can detect your cancer. The entire visit typically takes several hours.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States